Suppr超能文献

采用混合设计对伊曲康唑熔融挤出工艺的制剂研究。

Itraconazole formulation studies of the melt-extrusion process with mixture design.

作者信息

Rambali B, Verreck G, Baert L, Massart D L

机构信息

Farmaceutische Instituut, Vrije Universiteit Brussel, Brussels, Belgium.

出版信息

Drug Dev Ind Pharm. 2003 Jul;29(6):641-52. doi: 10.1081/ddc-120021313.

Abstract

Itraconazole is a poorly water soluble compound. One method to increase the aqueous solubility of itraconazole is through formation of a solid dispersion. The purpose of this study is to develop a 40% w/w itraconazole formulation through solid dispersion formation, using hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and hydroxypropylmethyl-cellulose (HPMC) as mixture components. The solid dispersion was obtained by melt-extrusion using a twin-screw corotating melt extruder. A D-optimal mixture design was applied for the development of the optimal itraconazole formulation. The itraconazole fraction varied between 20% w/w and 50% w/w in the mixture design and the HPMC and HP-beta-CD fractions varied between 10% w/w and 60% w/w. The itraconazole formulation was optimized by producing clear extrudates, minimizing the torque, and maximizing the glass transition temperature and the apparent itraconazole solubility in 0.1 N HCl. Regression models were developed for the torque, glass transition temperature, and apparent solubility of itraconazole. High itraconazole fraction in the mixture promoted a better melt processing (minimizes torque). High HPMC fraction (>33% w/w) resulted in clear extrudates, indicating a solid dispersion and resulted in high glass transition temperature of the melt. High HP-beta-CD fraction resulted in increased apparent itraconazole solubility in 0.1 N HCl. The optimal itraconazole formulation consisted of 45% w/w HPMC and 15% HP-beta-CD w/w.

摘要

伊曲康唑是一种水溶性较差的化合物。提高伊曲康唑水溶性的一种方法是通过形成固体分散体。本研究的目的是通过使用羟丙基-β-环糊精(HP-β-CD)和羟丙基甲基纤维素(HPMC)作为混合成分形成固体分散体来开发一种40%(w/w)的伊曲康唑制剂。使用双螺杆同向旋转熔融挤出机通过熔融挤出获得固体分散体。采用D-最优混合设计来开发最优的伊曲康唑制剂。在混合设计中,伊曲康唑的比例在20%(w/w)至50%(w/w)之间变化,HPMC和HP-β-CD的比例在10%(w/w)至60%(w/w)之间变化。通过生产透明挤出物、最小化扭矩以及最大化玻璃化转变温度和伊曲康唑在0.1N盐酸中的表观溶解度来优化伊曲康唑制剂。建立了关于扭矩、玻璃化转变温度和伊曲康唑表观溶解度的回归模型。混合物中高比例的伊曲康唑有利于更好的熔融加工(使扭矩最小化)。高比例的HPMC(>33%,w/w)会产生透明挤出物,表明形成了固体分散体,并导致熔体的玻璃化转变温度较高。高比例的HP-β-CD会导致伊曲康唑在0.1N盐酸中的表观溶解度增加。最优的伊曲康唑制剂由45%(w/w)的HPMC和15%(w/w)的HP-β-CD组成。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验